Study protocol for a prospective, multicentre, phase II trial on endoscopic treatment using two fully covered self-expandable metallic stents for benign strictures after hepaticojejunostomy Authors: Yuki Kawasaki, Susumu Hijioka, Yoshikuni Nagashio, Akihiro Ohba, Yuta Maruki, Kotaro Takeshita, Tetsuro Takasaki, Shin Yagi, Daiki Agarie, Yuya Hagiwara, Hidenobu Hara, Kohei Okamoto, Daiki Yamashige, Souma Fukuda, Masaru Kuwada, Shunsuke Kondo, Chigusa Morizane, Hideki Ueno, Takuji Okusaka Published: 2023 ABSTRACT IntroductionThe current endoscopic treatment for postoperative benign hepaticojejunostomy anastomotic stricture (HJAS) has a high technical success rate and is highly effective in the short term. However, long-term results have shown a high rate of stenosis recurrence, which indicates an insufficient response to treatment. Three prospective studies on fully covered self-expandable metallic stent (FC-SEMS) treatment for benign HJAS used the stenosis resolution rate as the primary endpoint, and no study has yet used the long-term non-stenosis rate (at 12 months) as the primary endpoint.Methods and analysisWe launched the ‘saddle-cross study’, which will be conducted as a multicentre, prospective intervention of endoscopic treatment using two modified FC-SEMSs (BONASTENT️ M-Intraductal) that have been improved for benign stenosis in patients with benign HJAS, with the long-term non-restenosis rate (at 12 months) as the primary endpoint. This study aims to evaluate the long-term non-restenosis rate (at 12 months) and safety of the saddle-cross technique for benign HJAS. We plan to enrol 50 participants.Ethics and disseminationThis study has been approved by the Certified Review Board of the National Cancer Center, Japan (CRB3180009). The results will be reported at various conferences and published in international peer-reviewed journals. STRENGTHS AND LIMITATIONS OF THIS STUDY No prospective studies have used long-term non-stricture rate as the primary endpoint in the treatment of benign bile duct stricture. No prospective studies have used long-term non-stricture rate as the primary endpoint in the treatment of benign bile duct stricture. The sample size required for a comparative study is enormous, and this trial is intended to be a validation study with many cases. The sample size required for a comparative study is enormous, and this trial is intended to be a validation study with many cases. This treatment procedure is limited to patients in whom the hepaticojejunostomy anastomotic stricture can be reached via the transgastrointestinal route. This treatment procedure is limited to patients in whom the hepaticojejunostomy anastomotic stricture can be reached via the transgastrointestinal route. Introduction Hepaticojejunostomy anastomotic stricture (HJAS) is a late complication that has been reported to occur in 3%–12% of patients undergoing pancreaticoduodenectomy.1–3 Postoperative transgastrointestinal endoscopic treatment for benign HJAS includes balloon dilation alone and temporary multiple biliary plastic or metal stenting. To date, the standard treatment in Japan is balloon dilation alone or temporary multiple biliary plastic stenting in addition to balloon dilation. The technical success rate of these treatments has been reported to be 86.8%–100%.4–8 In balloon dilation alone, the non-restenosis rate at 12 months has been reported to be 67.3%.4–6 In a report by Tomoda et al, the non-restenosis rate with multiple biliary plastic stenting combined with balloon dilation was 75% at 12 months.8 Recent studies have examined the efficacy of temporary implantation of fully covered self-expandable metallic stents (FC-SEMSs) for the treatment of benign bile duct strictures.9–15 These reports suggest that the temporary placement of an FC-SEMS is effective in improving the long-term non-stenosis rate and reducing the number of endoscopic procedures. The non-restenosis rate after the temporary placement of an FC-SEMS was 76.9% at 12 months, as reported by Devière et al.14 More recently, a new FC-SEMS (BONASTENT️ M-Intraductal, Standard Sci-Tech, Seoul, South Korea) with convex margins at both ends, a smaller central diameter, a cross-wired structure, and a 10 cm long lasso that was introduced for benign stenoses, has been improved and applied for benign bile duct strictures.13 In a report by Sato et al on FC-SEMS placement for benign HJAS, the modified FC-SEMS (BONASTENT️ M-Intraductal) was placed in 20 patients, and the metallic stent was removed after 3 months.15 In that report, the non-restenosis rate at 12 months was 87.5% (7/8), and long-term follow-up results from studies involving more patients are required. We previously reported the results of the endoscopic treatment of 20 cases of benign HJAS using two modified FC-SEMSs (BONASTENT️ M-Intraductal, saddle-cross technique).16 Technical and clinical success was achieved in all cases (20/20). Stenosis resolution was achieved at stent removal in all patients, and the non-restenosis rate at 12 months was 89.5% (17/19), achieving long-term patency in a larger number of cases than those reported previously. However, those results were from a single-centre, retrospective study; therefore, there is insufficient evidence to support the results of this treatment. Three prospective studies on FC-SEMS treatment of benign HJAS have been published,12 17 18 all of which used the stenosis resolution rate as the primary endpoint, and no study has yet used the long-term non-stenosis rate (at 12 months) as the primary endpoint. Therefore, we launched the ‘saddle-cross study’, which will be conducted as a multicentre, prospective, intervention of endoscopic treatment using two modified FC-SEMSs in patients with benign HJAS, with the long-term non-restenosis rate (at 12 months) as the primary endpoint. Methods and analysis Patient and public involvement In developing the protocol, the Certified Review Board at the National Cancer Center, Japan, reviewed the purpose and process of the study and whether the terminology was easy to understand for patients, with a representative from the public involved in the review process, and revised the implementation plan and explanatory documents. Objectives In this study, two modified FC-SEMSs (BONASTENT️ M-intraductal) will be used for the endoscopic treatment of benign HJAS to evaluate the clinical efficacy and safety of the treatment. Study setting This is a multicentre prospective study, and the planned treatment procedures after enrolment are shown in figure 1. CONSORT flow chart for a single-arm, open-label, phase II clinical trial on endoscopic treatment using two FC-SEMS for benign strictures after hepaticojejunostomy: The saddle-cross study. FC-SEMS, fully covered self-expandable metallic stent; HJAS, hepaticojejunostomy anastomotic stricture; IV-EUS, interventional endoscopic ultrasound; PTCD, percutaneous transhepatic cholangio-drainage. The CONSORT flow chart is a diagram that describes the cases excluded and the reasons for their exclusion at all stages of subject enrollment, allocation, follow-up, and analysis. Eleven facilities in Japan will be participating in this study, including the National Cancer Center Hospital, Japan, International University of Health and Welfare, Mita Hospital, Mie University Hospital, Fukuoka University Hospital, Kumamoto University Hospital, Dokkyo Medical University Saitama Medical Center, Tokyo Metropolitan Bokuotoh Hospital, Saitama Medical Center Jichi Medical University, Saiseikai Kawaguchi General Hospital, Subaru Health Insurance Society Ota Memorial Hospital and Keiyu Hospital. Patients who meet the eligibility criteria at each facility will be introduced to the study using an explanatory document, and those who will give their consent will be enrolled. Endpoints Primary endpoint and key secondary endpoint The purpose of this study is to evaluate the long-term non-restenosis rate (at 12 months) and safety of the saddle-cross technique for benign HJAS. The primary endpoint is the long-term non-restenosis rate (at 12 months), and the key secondary endpoint is the adverse event rate. Secondary endpoints In our pilot study, we achieved technical and clinical success in all patients. In this prospective multicentre study, the secondary endpoints are the (1) clinical success rate of endoscopic HJAS dilatation with two modified FC-SEMSs, (2) technical success rate of endoscopic HJAS dilatation with two modified FC-SEMSs, (3) procedure time, (4) time to restenosis, (5) rate of spontaneous stent dislodgment and (6) time to stenosis recurrence in cases of spontaneous stent dislodgment, for comparisons with the conventional standard treatment and to evaluate efficacy. Eligibility criteria We will be enrolling patients who meet criteria 1–7.No tumour is found at the anastomotic site on imaging (contrast-enhanced CT or MR cholangiopancreatography (MRCP)), no hepatic duct stone is found, and benign HJAS is suspected (regardless of patients who have previously received treatment for benign HJAS, except for those who have been treated with the saddle-cross technique).Cholangitis that meets any of the following criteria within 28 days before enrolment: (1) fever, (2) abdominal pain and (3) hepatic dysfunction conforming to any of the following: (a) total bilirubin level of >1.5 mg/dL, (b) aspartate transaminase level of >100 U/L or (c) alanine transferase level of >100 U/L.The patient meets the indications for the saddle-cross technique, except for the necessary endoscopic retrograde cholangiopancreatography findings during surgery or CT and MRCP findings.No bleeding tendency (platelet count of ≥50 ×109/L and prothrombin activity at 50%).Eastern Cooperative Oncology Group Performance Status: 0, 1 or 2.Age ≥20 yearsThe patient’s free and voluntary written consent to participate in the study has been obtained. We will be enrolling patients who meet criteria 1–7. No tumour is found at the anastomotic site on imaging (contrast-enhanced CT or MR cholangiopancreatography (MRCP)), no hepatic duct stone is found, and benign HJAS is suspected (regardless of patients who have previously received treatment for benign HJAS, except for those who have been treated with the saddle-cross technique). No tumour is found at the anastomotic site on imaging (contrast-enhanced CT or MR cholangiopancreatography (MRCP)), no hepatic duct stone is found, and benign HJAS is suspected (regardless of patients who have previously received treatment for benign HJAS, except for those who have been treated with the saddle-cross technique). Cholangitis that meets any of the following criteria within 28 days before enrolment: (1) fever, (2) abdominal pain and (3) hepatic dysfunction conforming to any of the following: (a) total bilirubin level of >1.5 mg/dL, (b) aspartate transaminase level of >100 U/L or (c) alanine transferase level of >100 U/L. Cholangitis that meets any of the following criteria within 28 days before enrolment: (1) fever, (2) abdominal pain and (3) hepatic dysfunction conforming to any of the following: (a) total bilirubin level of >1.5 mg/dL, (b) aspartate transaminase level of >100 U/L or (c) alanine transferase level of >100 U/L. The patient meets the indications for the saddle-cross technique, except for the necessary endoscopic retrograde cholangiopancreatography findings during surgery or CT and MRCP findings. The patient meets the indications for the saddle-cross technique, except for the necessary endoscopic retrograde cholangiopancreatography findings during surgery or CT and MRCP findings. No bleeding tendency (platelet count of ≥50 ×109/L and prothrombin activity at 50%). No bleeding tendency (platelet count of ≥50 ×109/L and prothrombin activity at 50%). Eastern Cooperative Oncology Group Performance Status: 0, 1 or 2. Eastern Cooperative Oncology Group Performance Status: 0, 1 or 2. Age ≥20 years Age ≥20 years The patient’s free and voluntary written consent to participate in the study has been obtained. The patient’s free and voluntary written consent to participate in the study has been obtained. The indications for the saddle-cross technique are as follows. The indications for the saddle-cross technique are as follows. This study treatment consists of the placement of two modified FC-SEMSs in the standard technique for the treatment of benign HJAS. The procedural aspect of the placement of two modified FC-SEMSs will be limited to patients who meet the following criteria on cholangiography based on CT, MRI and endoscopic retrograde cholangiopancreatography. Surgical anastomosis is a one-hole. Surgical anastomosis is a one-hole. The severity of HJAS is defined based on the anastomotic diameter as follows: normal >8 mm; mild ≤8 and 68 mm; mild ≤8 and 6